Shipping Office Stock vs. Prescriptions: $15M Case Study for Omnicare
Spread the love

Shipping Office Stock vs. Prescriptions: $15M Case Study for Omnicare

Omnicare, a leading provider of closed-door pharmacy services, agreed to pay more than a $15 million civil penalty for allowing opioids and other controlled substances to be dispensed without a valid prescription. The fine zeroes in on a common issue amongst pharmacies – discerning between office stock and shipping pursuant to a prescription. In addition to the penalty, the Memorandum of Agreement with the Drug Enforcement Administration (DEA) will require Omnicare to increase its auditing and monitoring of emergency kits placed at long-term care facilities.

To read the full press release from the DEA, please read here.

0 Comments

Submit a Comment

Your email address will not be published.